Molnupiravir’s authorisation was premature
On 1 October 2021 Merck issued a press release1 reporting an interim analysis of Move-Out, a phase 3 randomised placebo controlled trial in unvaccinated adults with confirmed SARS-Co-V infection and…
Read Original Article: Molnupiravir’s authorisation was premature »
